个人简介

生命科学与医学部教授、医学博士、药理学博士后、博士研究生导师、副院长。西部资源生物与现代生物技术教育部重点实验室副主任。2010年7月皇冠APP下载官网博士毕业，获医学博士学位（导师：林瑞超教授），同年留校生命科学与医学部从事科研和教学工作，讲师职称；2012年4月破格晋升副教授职称；2015年6月，特别评审晋升教授职称；2011年1月和2014年6月分别获得硕士研究生和博士研究生指导资格；2012年7月-2015年4月，第四军医大学药学院从事药理学博士后工作（导师：梅其炳教授）。2014年-2015年，University of California Irvine做访问学者，访问学者期间与肾脏病专家Nosratola D. Vaziri教授进行合作研究慢性肾脏病的病理机制及其中药抗肾间质纤维化。2010年-至今在皇冠APP下载官网中药系从事科研和教学工作。

兼职SCI期刊Frontiers in Medicine副主编、Pharmacognosy Magazine编辑、Scientific Reports高级编委、American Journal of Nephrology、Molecular Medicine Reports、Experimental and Therapeutic Medicine编委；《药物分析杂志》和皇冠APP下载官网学报（自然科学版）编委；教育部学科（中药学）评估通信评议人、教育部新增博士硕士学位（中药学）授权审核通讯评议人；世界中医药学会联合会临床用药安全研究专业委员会常务理事、中国中药协会肾病中药发展研究专业委员会常委、中国药理学会肾脏药理专业委员会委员、American Society of Nephrology会员。

主要从事慢性肾脏病的发病机制及中药提取物和活性成分抗肾间质纤维化研究。在猪苓、茯苓皮、泽泻等利尿中药的化学成分的系统研究、活性部位及单体化合物的利尿活性和肾保护活性（药理学）、药代动力学和代谢组学方面取得了一系列的创新性成果。以课题负责人承担国家自然科学基金青年基金和面上项目、科技部“重大新药创制”科技重大专项子课题、陕西省国际合作项目等10余项；2013年入选教育部“新世纪优秀人才支持计划”；2012年获全国百篇优秀博士学位论文提名奖、中国药学会-赛诺菲青年生物药物奖和第九届陕西省青年科技奖；2011年获中国药理学会第十五届施维雅青年药理学工作者奖；2010年获陕西省科技进步奖二等奖；2017年获陕西省高等学校科学技术奖一等奖

2009年以来，以第一作者或通讯作者在Nature Communications (IF=11.878)、Trends in Pharmacological Sciences (Cell子刊，IF=11.523)、Ageing Research Reviews (IF=10.390)、Medicinal Research Reviews (IF=9.791)、British Journal of Pharmacology、Redox Biology等国际期刊发表SCI论文107篇，H-index为42，其中10篇通讯作者论文入选ESI热点(0.1%)引用论文和12篇通讯作者论文入选ESI高被引用(1%)论文；全部论文被引用超过6200次；出版专著三部；以第1发明人授权国家发明专利6项；参加国内外学术会议20余次（10次口头报告）等。 指导的博士研究生和硕士研究生已有18人次获得国家研究生奖学金。

主要研究方向：

天然产物化学、中药药理学、系统生物学、生物学、分子生物学、生物化学、生物信息学

社会兼职：

1. 国际期刊副主编（Associate Editor）

Frontiers in Medicine (SCI收录期刊)

Current Metabolomics and Systems Biology (ESCI收录期刊)

2. 国际期刊编辑（Editor）

Pharmacognosy Magazine 编辑 (SCI收录期刊)

3. 国际期刊编委和编辑（Editorial Board Member）

Scientific Reports 高级编委 (SCI收录期刊)

American Journal of Nephrology 编委 (SCI收录期刊)

Molecular Medicine Reports编委 (SCI收录期刊)

Experimental and Therapeutic Medicine编委 (SCI收录期刊)

药物分析杂志 编委

皇冠APP下载官网学报（自然科学版）编委

4. 教育部双一流学科（中药学）评估通信评议人

5. 教育部新增博士硕士学位（中药学）授权审核通讯评议人

6. 教育部全国博士学位论文抽检通信评议人

7. 世界中医药学会联合会临床用药安全研究专业委员会，常务理事

8. 中国中药协会肾病中药发展研究专业委员会 常委

9. 中国药理学会肾脏药理专业委员会，委员

10. American Society of Nephrology, Member

承担的科研项目

1) RAS抑制剂茯苓皮三萜酸利尿及抗肾间质纤维化物质基础及作用机制研究(81872985)，国家自然科学基金-面上项目 (起止时间：2019.01-2022.12)

2) 基于NF-κB/Nrf2信号通路和脂质组学技术探讨猪苓的利尿物质基础抗肾纤维化的机制(81673578)，国家自然科学基金-面上项目 (起止时间：2017.01-2020.12)

3) 猪苓及麦角甾酮对马兜铃酸肾病的保护作用及其机制研究(81001622)，国家自然科学基金-青年项目 (起止时间：2011.10-2013.12)

4) 探讨膜性肾病中医药疗效作用机制及靶点的系统生物学研究 (2019YFC1709405)，国家重点研发计划-中医药现代化研究重点专项分课题（起止时间：2019.12-2021.12）

5） 中药质量安全检测和风险控制技术平台(2014ZX09304307-02)，科技部十二五重大新药创制科技重大专项子课题 (起止时间：2014.01-2016.12)

6) 猪苓甾酮一类新药研究(2011ZX09401-308-034)，科技部十二五重大新药创制科技重大专项子课题 (起止时间：2012.01-2014.12)

7) 肾康注射液的药效物质基础及其作用机制研究(2019ZDLSF04-04-02)，陕西省科技计划项目-重点产业创新链(群)-社会发展领域(起止时间：2019.01-2021.12)

8） 茯苓皮防治慢性肾病的物质基础及基于代谢组学作用机制(2012M521831) 中国博士后科学基金第52批面上资助基金

9) 茯苓皮的利尿活性成分分离及其防治慢性肾衰竭研究(2014T70984) 中国博士后科学基金第七批特别资助基金

10) 麦角甾酮的合成工艺优化及其治疗慢性肾衰竭的药理学研究(2013KW31-01)，陕西省国际科技合作项目

主要研究成果

2009年-至今发表的第一或通讯作者SCI论文(*表示通信作者)
1. Dan-Qian Chen, Gang Cao, Hua Chen, Christos P. Argyopoulos, Hui Yu, Wei Su, Lin Chen, David C. Samuels, Shougang Zhuang, George P. Bayliss, Shilin Zhao, Xiao-Yong Yu, Nosratola D. Vaziri, Ming Wang, Dan Liu, Jia-Rong Mao, Shi-Xing Ma, Jin Zhao, Yuan Zhang, You-Quan Shang, Huining Kang, Fei Ye, Xiao-Hong Cheng, Xiang-Ri Li, Li Zhang, Mei-Xia Meng, Yan Guo, Ying-Yong Zhao*. Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan. Nature Communications 2019;10:1476 [IF=12.353] (一区TOP期刊，ESI热点论文和ESI高被引论文)
2. Dan-Qian Chen, Ya-Long Feng, Gang Cao, Ying-Yong Zhao*. Natural products as a source for antifibrosis therapy. Trends in Pharmacological Sciences 2018; 39(11):937-952. [IF=12.108] (一区TOP期刊，ESI热点论文和ESI高被引论文)
3. He-He Hu#, Gang Cao#, Xia-Qing Wu#, Nosratola D. Vaziri, Ying-Yong Zhao*. Wnt signaling pathway in aging-related tissue fibrosis and therapies. Ageing Research Reviews 2020;60:101063. [IF=10.390] (一区TOP期刊)
4. Ya-Long Feng, Dan-Qian Chen, Nosratola D. Vaziri, Yan Guo, Ying-Yong Zhao*. Small molecule inhibitors of epithelial-mesenchymal transition for the treatment of cancer and fibrosis. Medicinal Research Reviews 2020;40(1):54-78. [IF=9.791] (一区TOP期刊)
5. Hua Chen, Gang Cao, Dan-Qian Chen, Ming Wang, Nosratola D. Vaziri, Zhi-Hao Zhang, Jia-Rong Mao, Xu Bai, Ying-Yong Zhao*. Metabolomics insights into activated redox signaling and lipid metabolism dysfunction in chronic kidney disease progression. Redox Biology 2016;10:168–178. [5年IF=9.038](一区TOP期刊，ESI热点论文)
6. Dan-Qian Chen, Gang Cao, Hua Chen, Dan Liu, Wei Su, Xiao-Yong Yu, Nosratola D. Vaziri, Xiu-Hua Liu, Xu Bai, Li Zhang, Ying-Yong Zhao*. Gene and protein expressions and metabolomics exhibit activated redox signaling and wnt/β-catenin pathway are associated with metabolite dysfunction in patients with chronic kidney disease. Redox Biology 2017;12: 505-521. [5年IF=9.038] (一区TOP期刊，ESI热点论文和ESI高被引论文)
7. Jie Ping, Olufunmilola Oyebamiji, Hui Yu, Scott Ness, Jeremy Chien, Fei Ye, Huining Kang, David Samuels, Sergey Ivanov, Danqian Chen, Ying-yong Zhao* Yan Guo*. MutEx: a multifaceted gateway for exploring integrative pan-cancer genomic data. Briefings in Bioinformatics 2020; doi: 10.1093/bib/bbz08. [IF=9.101] (二区TOP期刊)
8. Ya-Long Feng#, Gang Cao#, Dan-Qian Chen#, Nosratola D. Vaziri, Lin Chen, Jun Zhang, Ming Wang, Yan Guo, Ying-Yong Zhao*. Microbiome-metabolomics reveals gut microbiota associated with glycine-conjugated metabolites and polyamine metabolism in chronic kidney disease. Cellular and Molecular Life Sciences 2019;76(24):4961-4978. [IF=7.041]
9. Ming Wang#, Dan-Qian Chen#, Lin Chen, Gang Cao, Hui Zhao, Dan Liu, Nosratola D. Vaziri, Yan Guo, Ying-Yong Zhao*. Novel inhibitors of the cellular RAS components, Poricoic acids, target Smad3 phosphorylation and Wnt/β-catenin pathway against renal fibrosis. British Journal of Pharmacology 2018;175(13):2689-2708. [IF=6.583] (TOP期刊，ESI高被引论文)
10. Hua Miao#, Gang Cao#, Xia-Qing Wu#, Yuan-Yuan Chen#, Dan-Qian Chen, Lin Chen, Nosratola D. Vaziri, Ya-Long Feng, Wei Su, Yi Gao, Shougang Zhuang, Xiao-Yong Yu, Li Zhang, Yan Guo, Ying-Yong Zhao*. Identification of endogenous 1-aminopyrene as a novel mediator of progressive chronic kidney disease via aryl hydrocarbon receptor activation. British Journal of Pharmacology 2020; doi: 10.1111/bph.15062. [IF=6.583] (TOP期刊)
11. Dan-Qian Chen#, Ya-Long Feng#, Lin Chen, Jing-Ru Liu, Ming Wang, Nosratola D. Vaziri, Ying-Yong Zhao*. Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/Axl-NF-κB/Nrf2 axis. Free Radical Biology and Medicine 2019;134:484-497. [IF=6.020] (TOP期刊，ESI高被引论文)
12. Yuan-Yuan Chen#, Xiao-Yong Yu#, Lin Chen, Nosratola D. Vaziri, Shuang-Cheng Ma*, Ying-Yong Zhao*. Redox signaling in aging kidney and opportunity for therapeutic intervention through natural products. Free Radical Biology and Medicine 2019;141:141-149. [IF=5.657] (TOP期刊)
13. Ya-Long Feng#, Hua Chen#, Dan-Qian Chen, Nosratola D. Vaziri, Wei Su, Shi-Xing Ma, You-Quan Shang, Jia-Rong Mao, Xiao-Yong Yu, Li Zhang, Yan Guo, Ying-Yong Zhao*. Activated NF-κB/Nrf2 and Wnt/β-catenin pathways are associated with lipid metabolism in CKD patients with microalbuminuria and macroalbuminuria. Biochimica et Biophysica Acta-Molecular Basis of Disease 2019;1865(9):2317-2332. [IF=5.108] (TOP期刊)
14. Lin Chen#, Dan-Qian Chen#, Jing-Ru Liu, Jun Zhang, Nosratola D. Vaziri, Shougang Zhuang, Hua Chen, Ya-Long Feng, Yan Guo, Ying-Yong Zhao*. Unilateral ureteral obstruction causes gut microbial dysbiosis and metabolome disorders contributing to tubulointerstitial fibrosis. Experimental & Molecular Medicine 2019;51:38. [IF=5.583]
15. Ming Wang, Dan-Qian Chen, Min-Chang Wang, Hua Chen, Lin Chen, Dan Liu, Hui Zhao, Ying-Yong Zhao*. Poricoic acid ZA, a novel RAS inhibitor, attenuates tubulo-interstitial fibrosis and podocyte injury by inhibiting TGF-β/Smad signaling pathway. Phytomedicine 2017; 36:243-253. [IF=4.180] (TOP期刊)
16. Hua Chen, Tian Yang, Min-Chang Wang, Dan-Qian Chen, Yang Yang*, Ying-Yong Zhao*. Novel RAS inhibitor 25-O-methylalisol F attenuates epithelial-to-mesenchymal transition and tubulo-interstitial fibrosis by selectively inhibiting TGF-β-mediated Smad3 phosphorylation. Phytomedicine 2018;42:207-218. [IF=4.180] (TOP期刊，ESI高被引论文)
17. Dan-Qian Chen, He-He Hu, Yan-Ni Wang, Ya-Long Feng, Gang Cao, Ying-Yong Zhao*. Natural products for the prevention and treatment of kidney disease. Phytomedicine 2018;50:50-60 [IF=4.180] (TOP期刊)
18. Ying-Yong Zhao*, Xian-Long Cheng, Feng Wei, Xu Bai, Xiao-Jie Tan, Rui-Chao Lin, Qibing Mei. Intrarenal metabolomic investigation of chronic kidney disease and its TGF-β1 mechanism in induced-adenine rats using UPLC Q-TOF/HSMS/MSE. Journal of Proteome Research 2013;12(2):692–703. [IF=5.001]
19. Ying-Yong Zhao, Xuefeng Shen, Xu Chao, Charlene C. Ho, Xian-Long Cheng, Yongmin Zhang, Rui-Chao Lin, Ke-Jun Du, Wen-Jing Luo, Jing-Yuan Chen, Wen-Ji Sun. Ergosta-4,6,8(14),22-tetraen-3-one induces G2/M cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells. Biochimica et Biophysica Acta-General Subjects 2011;1810(4):384–390. [IF=5.000]
20. Lin Chen, Gang Cao, Ming Wang, Ya-Long Feng, Dan-Qian Chen, Nosratola D. Vaziri, Shougang Zhuang, Ying-Yong Zhao*. The matrix metalloproteinase-13 inhibitor poricoic acid ZI ameliorates renal fibrosis by mitigating epithelial-mesenchymal transition. Molecular Nutrition & Food Research 2019;63(13):1900132. [IF=5.151] (TOP期刊，ESI热点论文和ESI高被引论文)
21. Dan-Qian Chen, Gang Cao, Hui Zhao, Lin Chen, Tian Yang, Ming Wang, Nosratola D. Vaziri, Yan Guo, Ying-Yong Zhao*. Combined melatonin and poricoic acid A inhibits renal fibrosis through modulating the interaction of Smad3 and β-catenin pathway in AKI-to-CKD continuum. Therapeutic Advances in Chronic Disease 2019;10:2040622319869116. [IF=4.455]
22. Hua Chen#, Min-Chang Wang#, Yuan-Yuan Chen, Lin Chen, Yan-Ni Wang, Nosratola D. Vaziri, Hua Miao, Ying-Yong Zhao*. Alisol B 23-acetate attenuates CKD progression by regulating renin-angiotensin system and gut-kidney axis. Therapeutic Advances in Chronic Disease 2020;11: https://doi.org/10.1177/2040622320920025. [IF=4.455]
23. Tian Yang, Yuan-Yuan Chen, Jing-Ru Liu, Hui Zhao, Nosratola D. Vaziri, Yan Guo, Ying-Yong Zhao*. Natural products against renin-angiotensin system for antifibrosis therapy. European Journal of Medicinal Chemistry 2019;179:623-633. [IF=4.833] (TOP期刊)
24. Tian Yang#, Ya-Long Feng#, Lin Chen, Nosratola D. Vaziri, Ying-Yong Zhao*. Dietary natural flavonoids treating cancer by targeting aryl hydrocarbon receptor. Critical Reviews in Toxicology 2019; 49(5):445-460. [IF=4.771]
25. Dan-Qian Chen#, Hua Chen#, Lin Chen, Nosratola D. Vaziri, Ming Wang, Xiang-Ri Li, Ying-Yong Zhao*. The link between phenotype and fatty acid metabolism in advanced chronic kidney disease. Nephrology Dialysis Transplantation 2017;32(7):1154–1166. [IF=4.600] (ESI热点论文和ESI高被引论文)
26. Hui Zhao, Lin Chen, Tian Yang, Ya-Long Feng, Nosratola D. Vaziri, Bao-Li Liu, Qing-Quan Liu, Yan Guo, Ying-Yong Zhao*. Aryl hydrocarbon receptor activation mediates kidney disease and renal cell carcinoma. Journal of Translational Medicine 2019;17:302 [IF=4.197]
27. Yuan‑Yuan Chen, Dan‑Qian Chen, Lin Chen, Jing‑Ru Liu, Nosratola D. Vaziri, Yan Guo, Ying‑Yong Zhao*. Microbiome–metabolome reveals the contribution of gut–kidney axis on kidney disease. Journal of Translational Medicine 2019;17:5 [IF=4.197] (ESI高被引论文)
28. Hua Miao, Yu-Hui Zhao, Nosratola D. Vaziri, Dan-Dan Tang, Hua Chen, Han Chen, Mahyar Khazaeli, Mehrdokht Tarbiat-Boldaji, Leili Hatami, Ying-Yong Zhao*. Lipidomics biomarkers of diet-induced hyperlipidemia and its treatment with Poria cocos. Journal of Agricultural and Food Chemistry 2016;64(4):969-979. [IF=3.154] (一区TOP期刊)
29. Ming Wang, Dan-Qian Chen, Lin Chen, Dan Liu, Hui Zhao, Zhi-Hao Zhang, Nosratola D. Vaziri, Yan Guo, Ying-Yong Zhao*, Gang Cao. Novel RAS inhibitors poricoic acid ZG and poricoic acid ZH attenuate renal fibrosis via Wnt/β-catenin pathway and targeted phosphorylation smad3 signaling. Journal of Agricultural and Food Chemistry 2018;66(8):1828-1842. [IF=3.571] (一区TOP期刊，ESI热点论文和ESI高被引论文)
30. Hua Chen, Lin Chen, Dan Liu, Dan-Qian Chen, Nosratola D. Vaziri, Xiao-Yong Yu, Li Zhang, Wei Su, Xu Bai, Ying-Yong Zhao*. Combined clinical phenotype and lipidomic analysis reveals the impact of chronic kidney disease on lipid metabolism. Journal of Proteome Research 2017;16(4):1566-1578. [IF=3.950] (ESI高被引论文)
31. Ying-Yong Zhao*, Hui-Ling Wang, Xian-Long Cheng, Feng Wei, Xu Bai, Rui-Chao Lin, Nosratola D. Vaziri. Metabolomics analysis reveals the association between lipid abnormalities and oxidative stress, inflammation, fibrosis, and Nrf2 dysfunction in aristolochic acid-induced nephropathy. Scientific Reports 2015;5:12936 [IF=5.228]
32. Zhi-Hao Zhang, Feng Wei, Nosratola D. Vaziri, Xian-Long Cheng, Xu Bai, Rui-Chao Lin, Ying-Yong Zhao*. Metabolomics insights into chronic kidney disease and modulatory effect of rhubarb against tubulointerstitial fibrosis. Scientific Reports 2015;5:14472 [IF=5.228].
33. Zhi-Hao Zhang, Nosratola D. Vaziri, Feng Wei, Xian-Long Cheng, Xu Bai, Ying-Yong Zhao*. An integrated lipidomics and metabolomics reveal nephroprotective effect and biochemical mechanism of Rheum officinale in chronic renal failure. Scientific Reports 2016; 6: 22151. [IF=4.259]
34. Ying-Yong Zhao#, Xiang-Yang Qin#, Xian-Long Cheng, Xue-Ying Liu, Rui-Chao Lin, Yongmin Zhang, Xiao-Ye Li, Xiao-Li Sun, Wen-Ji Sun*. Rapid resolution liquid chromatography-mass spectrometry and high performance liquid chromatography-fluorescence detection for metabolism and pharmacokinetic studies of ergosta-4,6,8(14),22-tetraen-3-one. Analytica Chimica Acta 2010;675(2):199–206. [IF=4.310]
35. Zhi-Hao Zhang, Hua Chen, Nosratola D. Vaziri, Jia-Rong Mao, Li Zhang, Xu Bai, Ying-Yong Zhao*. Metabolomic signatures of chronic kidney disease of diverse etiologies in the rats and humans. Journal of Proteome Research 2016;15(10):3802–3812. [IF=4.268]
36. Fang Dou, Hua Miao, Jing-Wen Wang, Lin Chen, Ming Wang, Hua Chen, Ai-Dong Wen*, Ying-Yong Zhao*. An integrated lipidomics and phenotype study reveals protective effect and biochemical mechanism of traditionally used Alisma orientale Juzepzuk in chronic kidney disease. Frontiers in Pharmacology 2018;9:53. [IF=4.400]
37. Zhi-Hao Zhang, Ming-Hua Li, Dan Liu, Hua Chen, Dan-Qian Chen, Ning-Hua Tan, Shuang-Cheng Ma*, Ying-Yong Zhao*. Rhubarb protect against tubulointerstitial fibrosis by inhibiting TGF-β/Smad pathway and improving abnormal metabolome in chronic kidney disease. Frontiers in Pharmacology 2018;9:1029. [IF=4.400]
38. Lin Chen, Dan-Qian Chen, Ming Wang, Dan Liu, Hua Chen, Fang Dou, Nosratola D. Vaziri, Ying-Yong Zhao*. Role of RAS/Wnt/β-catenin axis activation in the pathogenesis of podocyte injury and tubulo-interstitial nephropathy. Chemico-Biological Interactions 2017;273:56–72. [IF=3.143] (ESI高被引论文)
39. Yan Guo*, Hui Yu, Danqian Chen, Ying-Yong Zhao*. Machine learning distilled metabolite biomarkers for early stage renal injury. Metabolomics 2019;16(1):4. [IF=3.167]
40. Hua Miao, Ming-Hua Li, Xu Zhang, Sheng-Jun Yuan, Charlene C. Ho, Ying-Yong Zhao*. The antihyperlipidemic effect of Fu-Ling-Pi is associated with abnormal fatty acid metabolism as assessed by UPLC-HDMS-based lipidomics. RSC Advances 2015;5(79):64208–64219. [IF=3.289]
41. Li Yan, Fan Song, Hua Li, Yao Li, Jie Li, Qiao-yan He, Zhang Di, Fang Wang, Meng Zhang, Hang Zhao, Tian Feng, Ying-Yong Zhao*, Si-wang Wang*. Submicron emulsion of cinnamaldehyde ameliorates bleomycin-induced idiopathic pulmonary fibrosis via inhibition of inflammation, oxidative stress and epithelial-mesenchymal transition. Biomedicine & Pharmacotherapy 2018;102:765-771. [IF=3.743]
42. Yan-Ni Wang, Shi-Xing Ma, Yuan-Yuan Chen, Lin Chen, Bao-Li Liu, Qing-Quan Liu, Ying-Yong Zhao*. Chronic kidney disease: biomarker diagnosis to therapeutic targets. Clinica Chimica Acta 2019;499:54-63. [IF=2.735]
43. Dan Liu, Lin Chen, Hui Zhao, Nosratola D. Vaziri, Shuang-Cheng Ma, Ying‑Yong Zhao*. Small molecules from natural products targeting the Wnt/β-catenin pathway as a therapeutic strategy. Biomedicine & Pharmacotherapy 2019; 116:108990. [IF=3.743](ESI热点论文)
44. Zhi-Hao Zhang, Jia-Rong Mao, Hua Chen, Wei Su, Yuan Zhang, Li Zhang, Dan-Qian Chen, Ying-Yong Zhao*, Nosratola D. Vaziri. Removal of uremic retention products by hemodialysis is coupled with indiscriminate loss of vital metabolites. Clinical Biochemistry 2017; 50(18):1078-1086. [IF=2.434]
45. Ying-Yong Zhao*, Ya-Long Feng, Xu Bai, Xiao-Jie Tan, Rui-Chao Lin, Qibing Mei. Ultra performance liquid chromatography-based metabonomic study of therapeutic effect of the surface layer of Poria cocos on adenine-induced chronic kidney disease provides new insight into anti-fibrosis mechanism. Plos One 2013; 8(3): e59617. [IF=3.534]
46. Ying-Yong Zhao*, Hua Chen, Ting Tian, Dan-Qian Chen, Xu Bai, Feng Wei. A pharmaco-metabonomic study on chronic kidney disease and therapeutic effect of ergone by UPLC-QTOF/HDMS. Plos One 2014; 9(12): e115467. [IF=3.234]
47. Ying-Yong Zhao*, Ya-Long Feng, Xiao Du, Zhi-Hui Xi, Xian-Long Cheng, Feng Wei. Diuretic activity the ethanol and aqueous extracts of the surface layer of poria cocos in rat. Journal of Ethnopharmacology 2012;144(3):775–778. [IF=3.728]
48. Ying-Yong Zhao*, Qi Su, Xian-Long Cheng, Xiao-Jie Tan, Xu Bai, Rui-Chao Lin. Pharmacokinetics, bioavailability, and metabolism of rhaponticin in rat plasma by UHPLC–Q–TOF/MS and UHPLC–DAD–MSn. Bioanalysis 2012;4(6):713–723. [IF=3.253]
49. Ying-Yong Zhao*, Xian-Long Cheng, Feng Wei, Xin-Yue Xiao, Wen-Ji Sun, Yongmin Zhang, Rui-Chao Lin. Serum metabonomics study of adenine-induced chronic renal failure rat by ultra performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. Biomarkers 2012;17(1):48–55. [IF=2.522]
50. Ying-Yong Zhao*, Jing Liu, Xian-Long Cheng, Xu Bai, Rui-Chao Lin. Urinary metabonomics study on biochemical changes in an experimental model of chronic renal failure by adenine based on UPLC Q-TOF/MS. Clinica Chimica Acta 2012;413(5–6):642–649. [IF=2.850]
51. Ying-Yong Zhao*, Xian-Long Cheng, Feng Wei, Xu Bai, Rui-Chao Lin. Ultra performance liquid chromatography coupled with electrospray and atmospheric pressure chemical (ESCi) ionization-quadrupole time-of-flight mass spectrometry with novel mass spectrometryElevated Energy (MSE) data collection technique: Determination and pharmacokinetics, tissue distribution and biliary excretion study of ergone in rat. Journal of Separation Science 2012;35(13):1619–1629. [IF=2.733]
52. Ying-Yong Zhao*, Xian-Long Cheng, Ji-Hong Cui, Xing-Rong Yan, Feng Wei, Xu Bai, Rui-Chao Lin. Effect of ergosta-4,6,8(14),22-tetraen-3-one (ergone) on adenine-induced chronic renal failure rat: A serum metabonomics study based on ultra performance liquid chromatography/high-sensitivity mass spectrometry coupled with MassLynx i-FIT algorithm. Clinica Chimica Acta 2012;413(19–20):1438–1445. [IF=2.850]
53. Ying-Yong Zhao#*, Xian-Long Cheng#, Rui Liu, Charlene C. Ho, Feng Wei, Sui-Hong Yan, Rui-Chao Lin, Yongmin Zhang, Wen-Ji Sun*. Pharmacokinetics of ergosterol in rats using rapid resolution liquid chromatography–atmospheric pressure chemical ionization multi-stage tandem mass spectrometry and rapid resolution liquid chromatography/tandem mass spectrometry. Journal of Chromatography B 2011;879(21):1945–1953. [IF=3.057]
54. Ying-Yong Zhao*, Li Zhang, Jia-Rong Mao, Xiao-Hong Cheng, Rui-Chao Lin, Wen-Ji Sun. Ergosta-4,6,8(14),22-tetraen-3-one isolated from Polyporus umbellatus prevents early renal injury in aristolochic acid-induced nephropathy rats. Journal of Pharmacy and Pharmacology 2011;63(12):1581–1561. [IF=2.175]
55. Yingyong Zhao#, Lili Wang#, Hua Miao, Charlene C. Ho, Jing Li, Xianlong Cheng, Yongmin Zhang, Ruichao Lin, Wen-Ji Sun*. LC method for the determination of rhaponticin in rat plasma, faeces and urine for application to pharmacokinetic studies. Chromatographia 2011;73(5–6):599–603. [IF=1.195]
56. Ying-Yong Zhao, Xian-Long Cheng, Yongmin Zhang, Xu Chao, Ye Zhao, Rui-chao Lin, Wen-ji Sun*. A fast and sensitive HPLC-MS/MS analysis and preliminary pharmacokinetic characterization of ergone in rats. Journal of Chromatography B 2010;878(1):29–33. [IF=2.971]
57. Ying-Yong Zhao, Xu Chao, Yongmin Zhang, Rui-Chao Lin, Wen-ji Sun*. Cytotoxic steroids from Polyporus umbellatus. Planta Medica 2010;76(15):1755–1758.[IF=2.369]
58. Ying-Yong Zhao, Xian-long Cheng, Yongmin Zhang, Ye Zhao, Rui-chao Lin. Simultaneous determination of eight major steroids from Polyporus umbellatus by high-performance liquid chromatography coupled with mass spectrometry detections. Biomedical Chromatography 2010;24(2):222–230. [IF=1.545]
59. Ying-Yong Zhao, Xiang-Yang Qin, Yongmin Zhang, Rui-chao Lin, Wen-Ji Sun, Xiao-Ye Li*. Quantitative HPLC method and pharmacokinetic studies of ergosta-4,6,8(14),22-tetraen-3-one, a natural product with diuretic activity from Polyporus umbellatus. Biomedical Chromatography 2010;24(10):1120–1124. [IF=1.545]
60. Ying-Yong Zhao, Xian-long Cheng, Ren-ming Xie, Xu Chao, Yongmin Zhang, Rui-chao Lin Wen-Ji Sun*. Bioactivity-directed isolation, identification of diuretic compounds from Polyporus umbellatus. Journal of Ethnopharmacology 2009;126(1):184–187. [IF=3.728]
61. Ying-Yong Zhao, Yongmin Zhang, Rui-Chao Lin, Wen-Ji Sun*. An expeditious HPLC method to distinguish Aconitum kusnezoffii from related species. Fitoterapia 2009;80(6):333–338. [IF=2.139]
62. Ying-Yong Zhao, Ye Zhao, Yong-min Zhang, Rui-chao Lin, Wen-ji Sun*. Qualitative and quantitative analysis of diuretic component ergone in Polyporus umbellatus by HPLC with fluorescence detection and HPLC-APCI-MS/MS. Pharmazie 2009;64(6):366–370. [IF=0.812]
63. Ying-Yong Zhao, Libin Yang, Minchang Wang, Lili Wang, Xian-long Cheng, Yongmin Zhang, Rui-chao Lin, Wen-ji Sun*. 1β-hydroxylfriedelin, a new natural pentacylic triterpene from the sclerotia of Polyporus umbellatus. Journal of Chemical Research 2009;11:699–701. [IF=0.550]
64. Ying-Yong Zhao, Xiang-Yang Qin, San-Ping Chen, Yongmin Zhang, Rui-Chao Lin, Wen-Ji Sun*. Crystal and molecular structure of rhaponticin from Rheum hotaoense. Journal of Chemical Crystallography 2011;41(3):409–414. [IF=0.566]
65. Ying-Yong Zhao*, Xuefeng Shen, Xian-Long Cheng, Feng Wei, Xu Bai, Rui-Chao Lin. Urinary metabonomics study on the protective effects of ergosta-4,6,8(14),22-tetraen-3-one on chronic renal failure in rats using UPLC Q-TOF/MS and a novel MSE data collection technique. Process Biochemistry 2012;47(12):1980–1987. [IF=3.225]
66. Ying-Yong Zhao*, Xian-Long Cheng, Feng Wei, Xu Bai, Rui-Chao Lin. Application of faecal metabonomics on an experimental model of tubulointerstitial fibrosis by ultra performance liquid chromatography/high-sensitivity mass spectrometry with MSE data collection technique. Biomarkers 2012;17(8):721–729. [IF=2.215]
67. Ying-Yong Zhao*, Li Zhang, Ya-Long Feng, Dan-Qian Chen, Zhi-Hui Xi, Xiao Du, Xu Bai, Rui-Chao Lin. Pharmacokinetics of 2,3,5,4’-tetrahydroxystilbene-2-O-β-D-glucoside in rat using ultra-performance LC-quadrupole TOF-MS. Journal of Separation Science 2013;36(5):863 –871. [IF=2.733]
68. Ying-Yong Zhao*, Xian-Long Cheng, Feng Wei, Xiao-Qiang Han, Xin-Yue Xiao, Rui-Chao Lin. Pharmacokinetics, bioavailability, and metabolism of 2,3,5,4′-tetrahydroxystilbene-2-O-β-D-glucoside in rats by ultra performance liquid chromatography–quadrupole time-of-flight mass spectrometry and high performance liquid chromatography-ultraviolet detection. Journal of Liquid Chromatography & Related Technologies 2013;36(6):717–730. [IF=0.706]
69. Ying-Yong Zhao*, Li Zhang, Feng-Ya Long, Xian-Long Cheng, Xu Bai, Feng Wei, Rui-Chao Lin. UPLC-Q-TOF/HSMS/MSE-based metabonomics for adenine-induced changes in metabolic profiles of rat faeces and intervention effects of ergosta-4,6,8(14),22-tetraen-3-one. Chemico-Biological Interactions 2013;301(1–3):31–38. [IF=2.982]
70. Ying-Yong Zhao*, Ping Lei, Dan-Qian Chen, Ya-Long Feng, Xu Bai. Renal metabolic profiling of early renal injury and renoprotective effects of poria cocos epidermis using UPLC Q-TOF/HSMS/MSE. Journal of Pharmaceutical and Biomedical Analysis 2013; 81–82(1):202–209. [IF=2.829]
71. Ying-Yong Zhao*, Hai-Tao Li, Ya-Long Feng, Xu Bai, Rui-Chao Lin. Urinary metabonomic study of the surface layer of poria cocos as an effective treatment for chronic renal injury in rats. Journal of Ethnopharmacology 2013;148(2):403–410. [IF=3.728]
72. Ying-Yong Zhao*, Dan-Dan Tang, Hua Chen, Jia-Rong Mao, Xu Bai, Xiao-Hong Cheng, Xin-Yue Xiao. Urinary metabolomics and biomarkers of aristolochic acid nephrotoxicity by UPLC-QTOF/HDMS. Bioanalysis 2015; 7(6):685–700. [IF=2.813]
73. Ying-Yong Zhao*, Xian-Long Cheng, Rui-Chao Lin. Lipidomics applications for discovering biomarkers of diseases in clinical chemistry. International review of cell and molecular biology 2014; 313: 1–26. [IF=3.419]
74. Ying-Yong Zhao*, Rui-Chao Lin. Metabolomics in nephrotoxicity. Advances in Clinical Chemistry 2014; 65:69–89. [IF=4.722]
75. Hua Chen, Hua Miao, Ya-Long Feng, Ying-Yong Zhao*, Rui-Chao Lin. Metabolomics in dyslipidemia. Advances in Clinical Chemistry 2014; 66:101–119. [IF=4.722]
76. Ying-Yong Zhao*, Nosratola D. Vaziri, Rui-Chao Lin. Lipidomics: new insight into kidney disease. Advances in Clinical Chemistry 2015; 68: 153–175. [IF=4.722]
77. Ying-Yong Zhao*. Metabolomics in chronic kidney disease. Clinica Chimica Acta 2013;422: 59–69. [IF=2.764]
78. Ying-Yong Zhao*. Traditional uses, phytochemistry, pharmacology, pharmacokinetics and quality control of Polyporus umbellatus (Pers.) Fries: A review. Journal of Ethnopharmacology 2013; 194(1):35–48. [IF=2.998]
79. Ying-Yong Zhao*, Rui-Chao Lin. UPLC–MSE application in disease biomarker discovery: the discoveries in proteomics to metabolomics. Chemico-Biological Interactions 2014; 215(1):7–16. [IF=2.577]
80. Ying-Yong Zhao*, Shao-Ping Wu, Shuman Liu, Yongmin Zhang, Rui-Chao Lin. Ultra-performance liquid chromatography-mass spectrometry as a sensitive and powerful technology in lipidomic applications. Chemico-Biological Interactions 2014; 220:181–192. [IF=2.577]
81. Ying-Yong Zhao*, Xian-Long Cheng, Nosratola D. Vaziri, Shuman Liu, Rui-Chao Lin. UPLC-based metabonomics applications for discovering biomarkers of diseases in clinical chemistry. Clinical Biochemistry 2014;47(15):16-26. [IF=2.606]
82. Ting Tian, Hua Chen, Ying-Yong Zhao*. Traditional uses, phytochemistry, pharmacology, toxicology and quality control of Alisma orientale (Sam.) Juzep: A review. Journal of Ethnopharmacology 2014; 158: 373–387. [IF=2.998]
83. Ying-Yong Zhao*, Xian-long Cheng, Rui-Chao Lin, Feng Wei. Lipidomics applications for diseases biomarker discovery in mammal models. Biomarkers in Medicine 2015; 9(2):153–168. [IF=2.179]
84. Ying-Yong Zhao#*, Hua Miao#, Xian-Long Cheng, Feng Wei. Lipidomics: novel insight into the biochemical mechanism of lipid metabolism and dysregulation-associated disease. Chemico-Biological Interactions 2015; 240: 220–238 [IF=2.618]
85. Dan-Qian Chen, Hua Chen, Lin Chen, Dan-Dan Tang, Hua Miao, Ying-Yong Zhao*. Metabolomic application in toxicity evaluation and toxicological biomarker identification of natural product. Chemico-Biological Interactions 2016; 252: 114–130. [IF=3.143]
86. Hua Chen, Ting Tian, Hua Miao, Ying-Yong Zhao*. Traditional uses, fermentation, phytochemistry and pharmacology of Phellinus linteus: A review. Fitoterapia 2016, 113: 6–26. [IF=2.698]
87. Ming Wang, Lin Chen, Dan Liu, Hua Chen, Dan-Dan Tang, Ying-Yong Zhao*. Metabolomics highlights pharmacological bioactivity and biochemical mechanism of traditional Chinese medicine. Chemico-Biological Interactions 2017; 273:133–141. [IF=3.143] (ESI高被引论文)
88. Lin Chen, Tian Yang, De-Wen Lu, Hui Zhao, Ya-Long Feng, Hua Chen, Dan-Qian Chen, Nosratola D. Vaziri, Ying-Yong Zhao*. Central role of dysregulation of TGF-β/Smad in CKD progression and potential targets of its treatment. Biomedicine & Pharmacotherapy 2018; 101: 670–681. [IF=3.743] (ESI热点论文和ESI高被引论文)
89. Lin Chen, Wei Su, Hua Chen, Dan-Qian Chen, Ming Wang, Yan Guo, Ying-Yong Zhao*. Proteomics for biomarker identification and clinical application in kidney disease. Advances in Clinical Chemistry 2018; 85: 91–113. [IF=4.250] (ESI高被引论文)
90. He-He Hu, Dan-Qian Chen, Yan-Ni Wang, Ya-Long Feng, Gang Cao, Nosratola D. Vaziri, Ying-Yong Zhao*. New insights into TGF-β/Smad signaling in tissue fibrosis. Chemico-Biological Interactions 2018; 292: 76–83. [IF=3.143] (ESI热点论文和ESI高被引论文)
91. Hua Miao, Hua Chen, Songwen Pei, Xu Bai, Nosratola D. Vaziri, Ying-Yong Zhao*. Plasma lipidomics reveal profound perturbation of glycerophospholipids, fatty acids, and sphingolipids in diet-induced hyperlipidemia. Chemico-Biological Interactions 2015; 228: 79–87. [IF=2.618]
92. Ya-Long Feng, Ping Lei, Hua Chen, Ting Tian, Lu Yin, Dan-Qian Chen, Qibing Mei, Ying-Yong Zhao*, Rui-Chao Lin. Diuretic activity of some fractions of the epidermis of Poria cocos. Journal of Ethnopharmacology 2013, 150(3):1114-1118. [IF=3.728]
93. Ya-Long Feng, Hua Chen, Ting Tian, Dan-Qian Chen, Ying-Yong Zhao*, Rui-Chao Lin. Diuretic and anti-diuretic activities of the ethanol and aqueous extracts of Alismatis Rhizoma. Journal of Ethnopharmacology 2014, 154(2):386-390. [IF=3.728]
94. Dan-Qian Chen, Ya-Long Feng, Ting Tian, Hua Chen, Lu Yin, Ying-Yong Zhao*, Rui-Chao Lin. Diuretic and anti-diuretic activities of fractions of Alismatis Rhizoma. Journal of Ethnopharmacology 2014;157:114–118. [IF=3.728]
95. Chang Wang, Mei-Xia Meng, Xu-Lei Tang, Ke-Ming Chen, Li Zhang, Wei-Ning Liu, Ying-Yong Zhao*. The proliferation, differentiation and mineralization effects of puerarin on osteoblasts in vitro. Chinese Journal of Natural Medicines 2014; 12(6):436-442. [IF=1.114]
96. Hua Miao, Li Zhang, Dan-Qian Chen, Hua Chen, Ying-Yong Zhao*, Shuang-Cheng Ma*. Urinary biomarker and treatment mechanism of Rhizoma Alismatis on hyperlipidemia. Biomedical Chromatography 2017;31(4):e3829. [IF=1.729]
97. Hua Chen, Bin Yuan, Hua Miao, Yi Tan, Xu Bai, Ying-Yong Zhao*, Yun Wang. Urine metabolomics reveals new insights into hyperlipidemia and therapeutic effect of rhubarb. Analytical Methods 2015;7(7):3113–3123. [IF=1.915]
98. Dan-Qian Chen, Ya-Long Feng, Ting Tian, Xiang-Yang Qin, Ying-Yong Zhao*. Cloud-point extraction combined with liquid chromatography for determination of ergosterol, a natural product with diuretic activity, in rat plasma, urine and faeces. Journal of Analytical Methods in Chemistry 2013;2013:479056. [IF=0.948]
99. Yang Sun, Chun-Mei Hu, Guo-Bo Li, Sheng-Yong Yang, Lu-Sha Liu, Chun-Lei Tan, Song Wei, Xaio-Yun Hu, Ying-Yong Zhao*, Jun Fan. Studies on the binding of iosalantolactone to human serum albumin by molecular spectroscopy and modeling. Indian Journal of Chemistry - Section A: Inorganic, Physical, Theoretical and Analytical Chemistry, 2011, 50(11): 1547-1554. [IF=0.891]
100. Lushu Liu, Yang Sun, Song Wei, Xiaoyun Hu, Yingyong Zhao*, Jun Fan. Solvent effect on the absorption and fluorescence of ergone: Determination of ground and excited state dipole moments. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 2012;86:120–123. [IF=2.098]
101. Yang Sun, Yingyong Zhao*. Enhanced pharmacokinetics and anti-tumor efficacy of PEGylated liposomal rhaponticin and plasma protein binding ability of rhaponticin. Journal of Nanoscience and Nanotechnology 2012;12(10):7677–7684. [IF=1.563]
102. Yang Sun, Zhen Ji, Yingyong Zhao*, Xuhua Liang, Xiaoyun Hu, Jun Fan. Enhanced distribution and anti-tumor activity of ergosta-4,6,8(14),22-tetraen-3-one by polyethylene glycol liposomalization. Journal of Nanoscience and Nanotechnology 2013;13(2):1435–1439. [IF=1.563]
103. Xuhua Liang, Yang Sun, Wenyuan Zeng, Lusha Liu, Xuan Ma, Yingyong Zhao*, Jun Fan. Synthesis and biological evaluation of a folate-targeted rhaponticin conjugate. Bioorganic & Medicinal Chemistry 2013;21(1):178–185. [IF=2.951]
104. Xuhua Liang, Yang Sun, Lusha Liu, Xuan Ma, Xiaoyun Hu, Jun Fan, Yingyong Zhao*. Folate-functionalized nanoparticles for controlled ergosta-4,6,8(14),22-tetraen-3-one delivery. International Journal of Pharmaceutics 2013;441(1–2):1–8. [IF=3.785]
105. Yan Guo*, Hui Yu, David C Samuels, Wei Yue, Scott Ness, Ying-Yong Zhao*. Single-nucleotide variants in human RNA: RNA editing and beyond. Briefings in Functional Genomics 2019;18(1):30-39. [IF=3.783]
106. Nosratola D. Vaziri, Ying-Yong Zhao, Madeleine V Pahl. Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment. Nephrology Dialysis Transplantation 2016;31(5):737–746. [IF=4.600] (入选ESI高被引用论文)

著作：

1) 赵英永，林瑞超 著《猪苓的化学成分及其应用研究》. 北京：科学出版社，2011.

2) 赵英永 编著《中药猪苓的现代研究和应用》. 北京：化学工业出版社，2010.

3) 赵英永，等参编《天然产物成分NMR谱模拟特征及实例》. 北京：中国医药科技出版社，2009.

获得的教学和科研表彰

获奖：

个人荣誉

1) 2013年，入选教育部“新世纪优秀人才支持计划”（NCET-13-0954）（教育部）

2) 2012年，获全国百篇优秀博士学位论文提名奖（教育部）

3) 2012年，获陕西省优秀博士学位论文（陕西省学位委员会）

4) 2012年，获第九届陕西省青年科技奖（颁奖机构：中共陕西省委组织部、陕西省人力资源和社会保障厅、陕西省科学技术协会）

5) 2012年，获中国药学会-赛诺菲青年生物药物奖（中国药学会）

6) 2011年，获中国药理学会第十五届施维雅青年药理学工作者奖（中国药理学会）
成果奖

1) 2010年，中药基础物质分离分析与应用，获陕西省科学技术奖二等奖，获奖人：孙文基，绳金房，赵英永，刘海静，尚平平，赵晔，高海，戴涌，徐长根，乔蓉霞，陈千良

2) 2017年，利水渗湿中药肾保护的药效物质基础，获陕西高等学校科学技术奖一等奖，获奖人：赵英永，苗华，陈华，陈丹倩，程小红，毛加荣，范引科

授权发明专利：

1) 麦角甾酮在制备治疗慢性肾衰竭药物中的应用；发明人：赵英永，林瑞超，谢人明

2) 茯苓皮提取物及其在治疗慢性肾衰竭药物中的应用；发明人：赵英永，林瑞超，程显隆，魏锋

3) 茯苓皮提取物及其在制备利尿作用药物中的应用；发明人：赵英永, 林瑞超, 程显隆, 魏锋